Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model.
DNA-DNA crosslinks are the lethal cellular mechanism of bifunctional alkylating agent cytotoxicity. Novobiocin, an inhibitor of DNA topoisomerase II, impairs eukaryotic DNA repair of alkylating agent adducts and may increase the number of adducts and their resultant cytotoxicity in malignant cells. The effect of novobiocin on clonogenic survival and DNA crosslinking due to cisplatin (cDDP) and carmustine (BCNU) was studied. Novobiocin caused synergistic cytotoxicity in Chinese hamster ovary cells exposed to cDDP or BCNU. Novobiocin and cDDP increased the formation of DNA-DNA interstrand crosslinks six-fold greater than cDDP alone. The effect was schedule dependent. Novobiocin and cDDP or BCNU markedly reduced in vivo growth of a murine fibrosarcoma without increased host toxicity. As a modulating agent of cytotoxicity due to DNA-DNA crosslinking, novobiocin may enhance the clinical effectiveness of the alkylating agents in human cancer and offer insight into new therapeutic strategies.
D000477:Alkylating Agents / Q000627:therapeutic use*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002330:Carmustine / Q000627:therapeutic use; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000627:therapeutic use; D006224:Cricetinae; D003412:Cricetulus; D004247:DNA / Q000187:drug effects*; D004357:Drug Synergism; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy; D007939:Leukemia L1210 / Q000188:drug therapy; D051379:Mice; D009675:Novobiocin / Q000627:therapeutic use*; D010053:Ovary / Q000166:cytology / Q000187:drug effects; D059005:Topoisomerase II Inhibitors
D000477:Alkylating Agents; D059005:Topoisomerase II Inhibitors; D009675:Novobiocin; D004247:DNA; D002945:Cisplatin; D002330:Carmustine